-+ 0.00%
-+ 0.00%
-+ 0.00%

Iovance says FDA clears IND for IL-12 tethered TIL therapy IOV-5001

PUBT·06/01/2026 11:31:14
Listen to the news
Iovance says FDA clears IND for IL-12 tethered TIL therapy IOV-5001
  • FDA cleared Iovance’s IND for IOV-5001, an IL-12 tethered tumor-infiltrating lymphocyte therapy, enabling a Phase 1/2 basket trial.
  • Enrollment is slated for the second half of 2026; the study tests a one-time regimen without IL-2 in selected solid tumors.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.